QR kód

Real-World Utilization Patterns, Safety, and Efficacy of Tafamidis in Patients With Hereditary Transthyretin Amyloidosis in Japan

ABSTRACT: Purpose: Patients with hereditary transthyretin (ATTRv) amyloidosis experience progressive degeneration of the somatic and peripheral nervous system that can impair ambulation, autonomy, and quality of life (QOL). Tafamidis meglumine (tafamidis) is the first pharmacotherapy approved to sl...

Celý popis

Uloženo v:
Hlavní autoři: Hiroaki Konishi, PharmD, Hajime Abe, MD, PhD, Noriko Matsumoto, Yutaka Endo, Yoshiki Sekijima, MD, PhD, Mitsuharu Ueda, MD, PhD, Yukio Ando, MD, PhD
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2025-01-01
Edice:Current Therapeutic Research
Témata:
Efficacy
Hereditary transthyretin amyloidosis
Japan
Postmarketing surveillance
Safety
Tafamidis meglumine
On-line přístup:http://www.sciencedirect.com/science/article/pii/S0011393X25000189
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky